Kidney Week

Abstract: SA-PO0904

Systematic Review and Correlation Meta-Analysis of Glycemic Biomarkers Compared with Continuous Glucose Monitoring-Derived Metrics in CKD

Session Information

• Health Maintenance, Nutrition, and Metabolism
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Health Maintenance, Nutrition, and Metabolism

• 1500 Health Maintenance, Nutrition, and Metabolism

Authors

• Cuevas Budhart, Miguel Angel, Instituto Mexicano del Seguro Social, Mexico City, Mexico

Miguel Angel Cuevas Budhart, MS, MSc, PhD, RN

• Campos, Erwin Iván, Macrotech, Mexico City, Mexico

Erwin Iván Campos, MD

• Ramos, Alfonso, Macrotech, Mexico City, Mexico

Alfonso Ramos, MD

• Paniagua, Ramón, Instituto Mexicano del Seguro Social, Mexico City, Mexico

Ramón Paniagua, MD, PhD

Background

Assessment of glycemic control in chronic kidney disease (CKD) is challenging because HbA1c may be influenced by anemia, erythropoietin use, and altered erythrocyte turnover. Alternative biomarkers such as glycated albumin and fructosamine have been proposed, although comparative evidence against continuous glucose monitoring (CGM)-derived metrics remains limited.

Methods

A systematic review and correlation meta-analysis was conducted according to PRISMA recommendations. PubMed, Scopus, and Web of Science were searched for studies published between 2016 and 2026 evaluating HbA1c, glycated albumin, and fructosamine against CGM-derived metrics in adults with CKD. Correlations were pooled using random-effects models after Fisher z transformation. Heterogeneity was assessed using I².

Results

Ten studies were included, and six contributed to the meta-analysis. Glycemic biomarkers showed a moderate-to-high pooled correlation with CGM-derived metrics (r=0.70; 95% CI 0.61-0.78; I2=67.4%). Glycated albumin showed the strongest correlation (r=0.77; 95% CI 0.68-0.83; I2=0%), particularly in advanced CKD and dialysis populations. HbA1c showed lower correlations with substantial heterogeneity (r=0.67; 95% CI 0.47-0.80; I2=83.5%). Fructosamine showed greater variability and limited evidence.

Conclusion

Glycated albumin showed the most consistent correlation with CGM-derived metrics in CKD, particularly in advanced disease and dialysis. These findings suggest glycated albumin may be a more reliable surrogate marker of glycemic exposure than HbA1c when CGM is unavailable.

Acknowledgment

The authors acknowledge the support of the Unidad de Investigación Médica en Enfermedades Nefrológicas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social.